Quantum BioPharma Ltd. Ordinary Shares - Class B (Sub Voting) QNTM 深 沪
等待开盘 09-23 09:30:00 美东时间
18.49
-0.380
-2.01%
华盛通- 最 高19.17
- 今 开19.17
- 成交量 8.90万股
- 最 低 18.00
- 昨 收 18.87
- 总市值 7057.45万
- 52周最高 38.25
- 市盈率 静 --
- 换手率 2.33%
- 52周最低 2.70
- 委 比 -14.29%
- 总股本 381.69万
- 历史最高 909.5234
- 量 比 0.60
- 振 幅 6.20%
- 历史最低 2.89
- 每 手 1
- 风险率 7.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
Quantum BioPharma Ltd. has received a Product License from Health Canada for its natural health product, Qlarity, allowing its sale in Canada. Qlarity is recommended for energy production, metabolism support, fatigue reduction, and cognitive performance enhancement. The company has also licensed a similar product, unbuzzd™, for the U.S. market. Quantum BioPharma is focused on developing innovative biotech solutions for neurodegenerative and metab...
09-18 12:10
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an Investor Webinar on September 16, 2025, to discuss its Reg D 506(c) investment opportunity for the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. The webinar will feature Unbuzzd CEO John Duffy and other executives who will review the science and clinical trial results, as well as the...
09-12 11:50
Quantum BioPharma Wins Buy Rating And $45 Forecast From Kingswood On Promise Of MS Drug Lucid-MS
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
09-10 19:09
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
Quantum BioPharma Ltd. (NASDAQ: QNTM) has received a BUY rating and a US$45 price target from Kingswood Capital Partners, contingent on successful Phase 2 and 3 trials of Lucid-MS by 2028 and a commercial launch in 2029. The Company, focused on neurodegenerative and metabolic disorders, is developing Lucid-MS to address myelin degradation in multiple sclerosis. Additionally, Quantum BioPharma holds a 20.10% stake in Unbuzzd Wellness Inc., retaini...
09-10 11:00
Quantum BioPharma Announces Key Corporate Updates
Quantum Biopharma ( ($TSE:QNTM) ) has provided an update. On August 21, 2025, Q...
08-21 19:27
SharpLink Stock Is Trading Higher Monday: What's Going On?
SharpLink Gaming, Inc. (NASDAQ:SBET) shares are volatile Monday after the company entered into securities purchase agreements with five global institutional investors.
08-12 02:53
Why Quantum BioPharma (QNTM) Stock Is Soaring Today
Shares of Quantum BioPharma are surging in Monday morning trading. The stock is higher following a series of positive updates regarding its lead drug candidate for multiple sclerosis.
08-11 23:34
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
Quantum BioPharma Ltd. has signed an agreement with a leading CDMO to manufacture an oral formulation of Lucid-MS, a novel treatment for multiple sclerosis. The oral formulation will be used in the Company’s upcoming Phase 2 clinical trial to test Lucid-MS’s efficacy in restoring mobility lost due to MS. Lucid-MS is a first-in-class, neuroprotective compound that prevents demyelination in preclinical models. The Company is preparing an IND applic...
08-11 11:40
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
Quantum BioPharma Ltd. has announced advancements in a joint clinical study with Massachusetts General Hospital (MGH) using a PET tracer to monitor myelin integrity and demyelination in MS patients. The tracer, developed by Dr. Pedro Brugarolas, showed the ability to detect lesion differences not visible via conventional MRI, offering potential as a biomarker for assessing Quantum's investigational drug, Lucid-21-302. The study was published in t...
08-08 12:00
Quantum BioPharma Q2 EPS $(3.23) Compared With $(0.08) YoY
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(3.23) per share which missed the analyst consensus estimate of $(0.07) by 4514.29 percent. This is a 3937.5 percent decrease over losses of $(0.08) per share
08-07 19:48
